EBV VCA IgG ELISA Kit
Quick Overview for EBV VCA IgG ELISA Kit (ABIN1326837)
Target
See all EBV VCA IgG productsReactivity
Detection Method
Method Type
Application
Sample Type
-
-
Purpose
- Diluted patient serum is added to wells coated with purified antigen. IgG specific antibody, if present, binds to the antigen. All unbound materials are washed away and the enzyme conjugate is added to bind to the antibody-antigen complex, if present. Excess enzyme conjugate is washed off and substrate is added. The plate is incubated to allow the hydrolysis of the substrate by the enzyme. The intensity of the color generated is proportional to the amount of IgG specific antibody in the sample
-
Analytical Method
- Qualitative
-
-
-
-
Plate
- Pre-coated
-
Restrictions
- For Research Use only
-
-
-
Storage
- 4 °C
-
-
-
: "Effects of aging, cytomegalovirus infection, and EBV infection on human B cell repertoires." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 192, Issue 2, pp. 603-11, (2014) (PubMed).
-
-
- EBV VCA IgG (Anti-Epstein-Barr Virus Viral Capsid Antigen IgG (EBV VCA IgG))
-
Alternative Name
- EBV-VCA IgG
-
Target Type
- Antibody, Antibody
-
Background
- Epstein-Barr virus (EBV) is a herpes virus known to cause infectious mononucleosis (IM). EBV infection may demonstrate a wide spectrum of clinical symptoms. The majorities of primary EBV infections are transmitted via saliva, occur during childhood, and are sub-clinical. In the U.S., 50% of the population demonstrate EBV antibodies before the age of 5 years 80% by adulthood. Transfusion-associated EBV infections have also been reported. Epstein-Barr virus has also been associated in the pathogenisis of two human cancers, Burkitt's lymphoma and nasopharyngeal carcinoma. Burkitt's lymphoma is primarily observed in Sub-Sahara Africa, especially in African children, and in New Guinea. Nasopharyngeal carcinoma is observed in Asia, most notably in Southern China.
Target See all EBV VCA IgG products
-